Targeting autoimmunity with CD19-CAR T-cell therapy: efficacy and seroconversion in diffuse systemic sclerosis and rheumatoid arthritis

Le résumé fourni par la source

Dear Editor, Rapidly progressive diffuse SSc is a rare autoimmune connective-tissue disease characterized by heterogeneous clinical manifestations, making disease management challenging. Current therapeutic concepts are primarily aimed at suppressing inflammation and slowing down fibrotic remodelling, necessitating continuous, lifelong immunomodulatory therapy [1]. SSc can rarely coincide with RA, further complicating treatment [2]. B cells are considered key drivers of inflammation in both diseases. B-cell depletion with rituximab has shown efficacy in both SSc and RA but often fails to induce long-lasting remission [3, 4]. Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy has recently expanded the therapeutic armamentarium for autoimmune diseases, showing promising results in various SSc cases [5] and good tolerability in 30 patients with autoimmune diseases and a median follow-up of 12 months [6]. Additionally, one case report demonstrated the successful use of anti-CD19 CAR T-cell therapy in treating a patient with myasthenia gravis with coexisting RA [7]. Herein, we present the case of a 32-year-old female patient with a 6-year history of Scl-70-positive SSc and ACPA-positive RA. The patient presented with skin fibrosis, Raynaud’s phenomenon, recurrent digital ulcers, reduced oesophageal motility with reflux, pulmonary fibrosis and polyarthritis. Previous immunosuppressive treatments included glucocorticoids, methotrexate, azathioprine, hydroxychloroquine and tocilizumab. Furthermore, she was treated with nintedanib, sildenafil, nifedipine and repeated iloprost infusions. Despite these therapies, her course of SSc continuously progressed, although RA disease activity remained well-controlled (DAS28-CRP 2.02, CDAI 4). After discussing the risks and benefits of potential treatment options, the patient consented to undergo autologous anti-CD19 CAR-T-cell therapy in a shared decision.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.